Kingstone Capital Partners Texas LLC Invests $30.34 Million in Pfizer Inc. $PFE

Key Points

• Kingstone Capital Partners Texas LLC has made a significant new investment of approximately $30.34 million in Pfizer Inc., acquiring 1,251,657 shares during the second quarter.
• Recent research from various firms has influenced Pfizer's stock ratings, with target price adjustments from Morgan Stanley and Bank of America, along with a raise in rating from a "hold" to a "buy" by Wall Street Zen.
• Pfizer reported a strong quarterly earnings performance, with earnings per share of $0.78, surpassing estimates, and a revenue increase of 10.3% compared to the previous year.

Kingstone Capital Partners Texas LLC acquired a new stake in Pfizer Inc. (NYSE:PFE - Free Report) in the 2nd quarter, according to its most recent disclosure with the SEC. The fund acquired 1,251,657 shares of the biopharmaceutical company's stock, valued at approximately $30,340,000.

A number of other institutional investors have also recently made changes to their positions in the stock. Capital Advisory Group Advisory Services LLC lifted its holdings in Pfizer by 2.9% in the second quarter. Capital Advisory Group Advisory Services LLC now owns 13,542 shares of the biopharmaceutical company's stock valued at $328,000 after acquiring an additional 388 shares during the last quarter. Trust Co of the South lifted its stake in Pfizer by 1.5% in the 2nd quarter. Trust Co of the South now owns 29,386 shares of the biopharmaceutical company's stock valued at $712,000 after buying an additional 441 shares in the last quarter. Charter Oak Capital Management LLC lifted its stake in shares of Pfizer by 4.3% during the 2nd quarter. Charter Oak Capital Management LLC now owns 10,663 shares of the biopharmaceutical company's stock worth $258,000 after purchasing an additional 444 shares during the period. Members Trust Co increased its holdings in shares of Pfizer by 2.1% during the 1st quarter. Members Trust Co now owns 23,175 shares of the biopharmaceutical company's stock worth $587,000 after buying an additional 467 shares during the last quarter. Finally, Sutton Place Investors LLC grew its holdings in Pfizer by 5.6% during the 1st quarter. Sutton Place Investors LLC now owns 8,833 shares of the biopharmaceutical company's stock valued at $224,000 after purchasing an additional 472 shares in the last quarter. Institutional investors own 68.36% of the company's stock.

Wall Street Analysts Forecast Growth

A number of equities analysts have issued reports on the stock. Citigroup raised their target price on shares of Pfizer from $25.00 to $26.00 and gave the stock a "neutral" rating in a report on Wednesday, August 6th. Morgan Stanley lifted their price target on Pfizer from $32.00 to $33.00 and gave the stock an "equal weight" rating in a research report on Wednesday, August 6th. Wall Street Zen raised shares of Pfizer from a "hold" rating to a "buy" rating in a research note on Saturday. Berenberg Bank reduced their target price on shares of Pfizer from $28.00 to $25.00 and set a "hold" rating on the stock in a research report on Thursday, May 29th. Finally, Bank of America increased their price objective on shares of Pfizer from $27.00 to $28.00 and gave the stock a "neutral" rating in a research report on Wednesday, August 6th. Two analysts have rated the stock with a Strong Buy rating, four have given a Buy rating, eleven have assigned a Hold rating and one has assigned a Sell rating to the company's stock. According to data from MarketBeat.com, Pfizer currently has an average rating of "Hold" and an average price target of $28.12.

Pfizer Stock Performance

Shares of NYSE:PFE traded down $0.12 during trading on Friday, hitting $24.03. 86,201,583 shares of the stock traded hands, compared to its average volume of 42,502,152. The company has a fifty day moving average price of $24.63 and a two-hundred day moving average price of $24.20. Pfizer Inc. has a 52-week low of $20.92 and a 52-week high of $30.43. The company has a market cap of $136.62 billion, a price-to-earnings ratio of 12.78, a P/E/G ratio of 0.78 and a beta of 0.55. The company has a quick ratio of 0.85, a current ratio of 1.16 and a debt-to-equity ratio of 0.65.

Pfizer (NYSE:PFE - Get Free Report) last announced its earnings results on Tuesday, August 5th. The biopharmaceutical company reported $0.78 earnings per share for the quarter, topping the consensus estimate of $0.58 by $0.20. Pfizer had a net margin of 16.84% and a return on equity of 21.42%. The firm had revenue of $14.65 billion for the quarter, compared to the consensus estimate of $13.43 billion. During the same period in the prior year, the firm earned $0.60 EPS. The firm's revenue for the quarter was up 10.3% on a year-over-year basis. Pfizer has set its FY 2025 guidance at 2.900-3.100 EPS. As a group, equities analysts predict that Pfizer Inc. will post 2.95 EPS for the current year.

Pfizer Announces Dividend

The firm also recently announced a quarterly dividend, which was paid on Tuesday, September 2nd. Shareholders of record on Friday, July 25th were issued a dividend of $0.43 per share. The ex-dividend date was Friday, July 25th. This represents a $1.72 annualized dividend and a yield of 7.2%. Pfizer's payout ratio is currently 91.49%.

Pfizer Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.